Pregnant or Postpartum Women Invited to COVID-19 Vaccine Study

A new observational study has begun to evaluate the immune responses generated by COVID-19 vaccines administered to pregnant (750) or postpartum women (250), announced by the U.S. NIH on June 23, 2021.

Researchers will measure the development and durability of antibodies against SARS-CoV-2, the coronavirus that causes COVID-19, in women vaccinated during pregnancy or the first two postpartum months.

These researchers also will assess vaccine safety and evaluate the transfer of vaccine-induced antibodies to infants across the placenta and through breast milk.

The study, called MOMI-VAX, is sponsored and funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. MOMI-VAX is conducted by the Infectious Diseases Clinical Research Consortium. More information about the study, including a list of sites, is available on this website.